1996
DOI: 10.1016/s0002-9149(96)00606-6
|View full text |Cite
|
Sign up to set email alerts
|

Cost savings with nonthoracotomy implantable cardioverter-defibrillators

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0
1

Year Published

1997
1997
2008
2008

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 14 publications
(3 citation statements)
references
References 19 publications
0
2
0
1
Order By: Relevance
“…20 Average convalescent time was reduced from 11.6 days for epicardial/abdominal implants to 4.6 days for nonthoracotomy abdominal implants and to 2.9 days for nonthoracotomy pectoral implants. Compared with the epicardial/ abdominal group, average charges were reduced by 40% in the abdominal group and by 55% in the pectoral group using the transvenous lead system.…”
Section: The Future: Icd Technology and Patient Managementmentioning
confidence: 93%
“…20 Average convalescent time was reduced from 11.6 days for epicardial/abdominal implants to 4.6 days for nonthoracotomy abdominal implants and to 2.9 days for nonthoracotomy pectoral implants. Compared with the epicardial/ abdominal group, average charges were reduced by 40% in the abdominal group and by 55% in the pectoral group using the transvenous lead system.…”
Section: The Future: Icd Technology and Patient Managementmentioning
confidence: 93%
“…Neben den Ergebnissen anderer Untersuchungen [3,54,57] wird diese Aussage eindrucksvoll durch die Untersuchung von Mushlin et al gestützt [67]. Die Einführung transvenöser Elektrodensysteme war ein wesentlicher Punkt der Kostenreduktion und ermöglichte in Verbindung mit der deutlichen Größenreduktion der Defibrillatorgeneratoren eine technisch einfache Implantation bei einer zusätzlichen Verkürzung der Dauer des stationären Aufenthalts der Patienten [20]. Die in den letzten Jahren realisierte Verlängerung der Lebensdauer der implantierten Systeme ist ein weiterer zentraler Punkt, der zu einer Verbesserung der Kosteneffektivität beiträgt.…”
Section: Neuzner J Et Al Sozioökonomische Aspekte Der Behandlung Vounclassified
“…Specifically, Medtronic has never stated that the Transvene lead Models 6936/6966 “… have lower than expected longevity.” In fact, the Transvene leads, which were released in the US market in 1993, were state‐of‐the‐art at the time and were a significant improvement over the epicardial patch leads. The Transvene leads allowed more patients to be implanted due to the reduced morbidity and mortality and a significant reduction in hospital stay 2 …”
mentioning
confidence: 99%